Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of MK-8931 in Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
2012-005542-38Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of verubecestat in Alzheimer's disease (AD) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) at Week 104. Started Sep 2013; status: terminated.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-005542-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005542-38.